Morgan Stanley rates Vertex Pharma stock Buy at USD 665.00
Published on 10/08/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Morgan Stanley assigned Vertex Pharma stock a Buy rating and a USD 665.00 price target in a report dated October 7, 2026, according to Markets Insider. The call gives the upcoming earnings date and Vertex's pipeline milestones a sharper market context.
Three events shaped the story
On September 1, 2026, Vertex completed its USD 10.00 billion acquisition of Crinetics Pharmaceuticals, adding the acromegaly drug Palsonify and the pipeline candidate atumelnant, according to VentureAtlas.
On September 22, 2026, Vertex announced positive Phase 2b AMPLIFIED study results for inaxaplin in additional APOL1-mediated kidney disease populations, with interim AMPLITUDE data planned after 48 weeks of treatment, according to FinanzNachrichten. On October 7, 2026, Morgan Stanley's rating and USD 665.00 target became the latest dated event in this sequence.
What does the target imply?
The USD 665.00 target is stated in the original currency of Vertex's Nasdaq listing, while the Lang & Schwarz quote provides the euro reference for investors in Germany. The comparison is therefore directional rather than a combined return calculation.
Vertex reported USD 3.33 billion of revenue in the second quarter of 2026, up 12.50 percent from USD 2.96 billion in the second quarter of 2025, while net profit reached USD 1.10 billion versus USD 1.03 billion a year earlier, according to Markets Insider. The revenue increase gives the rating a current operating anchor, even as the stock remains exposed to execution risk across newer medicines.
Next dates are already set
Vertex will report third-quarter 2026 financial results on November 2, 2026, after the US market close, and will hold its earnings call at 4:30 p.m. ET, according to Vertex Pharmaceuticals. A November 30, 2026 PDUFA target date applies to the FDA decision on povetacicept for IgA nephropathy, according to VentureAtlas.
Stock trades below the prior close
Vertex Pharma stock was trading at EUR 447.33 at Lang & Schwarz on October 8, 2026 at 3:37 p.m. CEST, down 0.96 percent versus the prior close of EUR 451.65. On Nasdaq, the stock was last at USD 500.02 on October 8, 2026 at 9:45 a.m. EDT, inside its USD 402.58 to USD 560.25 52-week range; market capitalization was USD 126.9 billion as of the same date.
The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.
Vertex Pharmaceuticals stock facts
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 8, 2026, 3:37 p.m. CEST: EUR 447.33
- Change versus prior close: minus 0.96 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 451.65
- Market capitalization: USD 126.9 billion (as of October 8, 2026)
- 52-week range: USD 402.58-560.25 (as of October 8, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 2, 2026
Market context: Market report Nasdaq Composite.
